MedTrace Logo

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

NCT07502001 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-03-30

No results posted yet for this study

Summary

The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.

Conditions

Interventions

DRUG

Acetaminophen

Single dose; Administered orally

DRUG

Metformin

Single dose; Administered orally

DRUG

Warfarin

Single dose; Administered orally

DRUG

Atorvastatin

Single dose; Administered orally

DRUG

Digoxin

Single dose; Administered orally

DRUG

HDM1005 injection

Subcutaneous injection QW

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-08
Primary Completion
2026-12-01
Completion
2027-06-02
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07502001 on ClinicalTrials.gov